Nito Chikako, Suda Satoshi, Nitahara-Kasahara Yuko, Okada Takashi, Kimura Kazumi
Department of Neurological Science, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan.
Collaborative Research Center, Laboratory for Clinical Research, Nippon Medical School, Tokyo 113-8603, Japan.
Biomedicines. 2022 Mar 22;10(4):737. doi: 10.3390/biomedicines10040737.
Regenerative medicine aims to restore human functions by regenerating organs and tissues using stem cells or living tissues for the treatment of organ and tissue defects or dysfunction. Clinical trials investigating the treatment of cerebral infarction using mesenchymal stem cells, a type of somatic stem cell therapy, are underway. The development and production of regenerative medicines using somatic stem cells is expected to contribute to the treatment of cerebral infarction, a central nervous system disease for which there is no effective treatment. Numerous experimental studies have shown that cellular therapy, including the use of human dental pulp stem cells, is an attractive strategy for patients with ischemic brain injury. This review describes the basic research, therapeutic mechanism, clinical trials, and future prospects for dental pulp stem cell therapy, which is being investigated in Japan in first-in-human clinical trials for the treatment of patients with acute cerebral ischemia.
再生医学旨在通过利用干细胞或活组织再生器官和组织来恢复人体功能，以治疗器官和组织缺陷或功能障碍。正在进行使用间充质干细胞治疗脑梗死的临床试验，这是一种体干细胞疗法。利用体干细胞开发和生产再生药物有望为脑梗死的治疗做出贡献，脑梗死是一种尚无有效治疗方法的中枢神经系统疾病。大量实验研究表明，包括使用人牙髓干细胞在内的细胞疗法，对于缺血性脑损伤患者是一种有吸引力的策略。本综述描述了牙髓干细胞疗法的基础研究、治疗机制、临床试验及未来前景，日本正在对急性脑缺血患者进行首次人体临床试验来研究该疗法。
